Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World August 22, 2013 Phillip Broadwith	J&J buys Aragon's prostate cancer arm Hormonally-driven cancer drug discovery specialist Aragon Pharmaceuticals has been bought by Johnson & Johnson.
BusinessWeek May 23, 2005 Catherine Arnst	If It Works for Breast Cancer... Studies are under way to see if promising strategies used against breast cancer can be used to fight other killers, such as lung, colon, and prostate cancer.
Chemistry World February 23, 2009 Nina Notman	Resistant breast cancers re-sensitised to Tamoxifen A way to re-sensitise certain drug-resistant breast cancers to treatments such as Tamoxifen could offer better treatment for people with hard-to-beat cancers.
The Motley Fool May 8, 2009 Brian Orelli	Investing Against Breast Cancer Many companies are interested in both a cure and a large lucrative market. Which are the best investments now in this sector?
The Motley Fool March 26, 2007 Rich Duprey	Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note.
The Motley Fool March 29, 2007 Brian Lawler	Genentech Going Forward Genentech gives guidance for first-quarter sales numbers. Investors, take note.
BusinessWeek July 3, 2006 Catherine Arnst	A Ton Of Prevention The pros and cons of two drugs that may halve your risk of breast cancer.
BusinessWeek May 9, 2005 Catherine Arnst	Genentech's Lessons For Big Pharma The biotech company focuses on science -- not marketing, acquisitions, or patents.
The Motley Fool March 23, 2004 David Nierengarten	Genentech's Star Power How much higher can Genentech go?
The Motley Fool April 8, 2004 Brian Gorman	Genentech's Healthy Showing The company's first-quarter results were impressive, driven by pricey cancer drugs.
The Motley Fool June 29, 2007 Brian Lawler	Genentech's All Good The biotech's latest partnership deal is nothing to worry about. Investors, take note.
BusinessWeek June 6, 2005 Catherine Arnst	Better Odds Against Breast Cancer New treatments for breast cancer are more effective, and easier to live with
AskMen.com Sabrina Rogers	Can Men Get Breat Cancer? Breast cancer isn't just a chick thing. Although it is about 100 times more common among women and is a rare cause of death in men, the American Cancer Society estimates that, in 2004, approximately 1,450 American men will be diagnosed with this disease.
The Motley Fool October 1, 2008 Brian Orelli	3 Drugmakers With Multiple Shots on Goal Well-stocked pipelines could kick these drugmakers into super-high gear.
The Motley Fool January 12, 2005 Charly Travers	Forget Earnings; Think R&D Look at the big picture to find biotech companies with the most promise.
The Motley Fool May 4, 2009 Robert Steyer	Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success?
The Motley Fool April 13, 2007 Brian Lawler	Genentech Is Still Healthy The biopharma powerhouse announces its first-quarter financial results. Investors, take note.
The Motley Fool February 25, 2008 Brian Lawler	A Positive Surprise for Genentech Biopharma Genentech's lead drug gets a conditional OK to treat breast cancer.
BusinessWeek September 5, 2005 Michael Arndt	Fine-Tuning the Attack on Breast Cancer Genentech's Herceptin, the first drug approved for a specific group, helps patients who are genetically susceptible to a virulent form of the disease.
The Motley Fool August 27, 2007 Brian Lawler	Round 2 for Genentech Learn a lesson or two from Genentech's's dance with the FDA. The drugmaker's experience serves as a reminder of the fickle nature of the government agency, and the sometimes frustrating process of bringing a medication to market.
The Motley Fool July 15, 2008 Brian Lawler	Genentech Needs More Profit Power Another fine quarter of sales for the biotech company, but what about net earnings?
The Motley Fool May 2, 2011 Brian Orelli	Prostate Cancer Drug Roars Ahead Johnson & Johnson's buy of Cougar paid off, but look in the rear view mirror.
BusinessWeek July 31, 2006 Gene G. Marcial	Genentech Is More Robust Than It Looks Genentech, the world's second-largest biotech and an innovative developer of biotherapeutics, gets no favors from the Street.
The Motley Fool April 19, 2004 Charly Travers	4 Promising Biotech IPOs Several recently gone-public biotechs boast surprisingly interesting drug pipelines. From drugs for hepatitis to hopeful cancer treatments, watch out for these four biotech debutantes. If trials go smoothly, they may be the next up-and-coming stocks in the industry.
AskMen.com September 30, 2000 Joshua Levine	Male Breast Cancer Breast cancer is traditionally thought of as a female-related problem. Men, however, are as susceptible to the disease as women are. In many ways, the disease appears similarly in both sexes...
The Motley Fool May 10, 2005 Charly Travers	The Future of Cancer Therapy Biotech firm Exelixis is blazing a trail for long-term success. Should investors take notice?
The Motley Fool March 17, 2008 Brian Lawler	Genentech Takes Center Stage There might be more partnerships in store for this drugmaker.
Chemistry World November 30, 2006 Jessica Ebert	Morning After Pill Might Prevent Breast Cancer The active ingredient of the morning-after pill -- mifepristone, or RU-486 -- prevents the formation of mammary-cell tumours in mice with a mutation in the breast cancer susceptibility gene, BRCA1, report scientists.
The Motley Fool November 2, 2004 Charly Travers	Biotech's 5-Baggers: Part 3 Year after year, the hottest biotech companies with investors are those with drugs in development for the treatment of cancer.
Reactive Reports Issue 53 David Bradley	An Underarm Review A review of health effects of organometallic compounds suggests that aluminum compounds used in the manufacture of underarm antiperspirants may somehow be involved in an increased risk of breast cancer.
The Motley Fool January 15, 2008 Brian Lawler	Gauging Genentech Genentech releases its fourth-quarter results; in which revenues were up and adjusted earnings per share gained.
AskMen.com Jacob Franek	Prostate Cancer Treatment And Prevention Everything you wanted to know about prostate cancer in our three-part Prostate Cancer Guide.
AskMen.com Jacob Franek	Prostate Cancer Overview Everything you wanted to know and more about prostate cancer in this three-part prostate cancer guide.
BusinessWeek October 6, 2003 Arlene Weintraub	Drug Development, Genentech Style Its promising colon cancer fighter Avastin is a prime example of how the biotech "keeps following the science."
The Motley Fool October 16, 2007 Brian Lawler	Genentech Fitting Better Cancer treatment Avastin continues to surge for the biopharma with a jump on the competition. Investors, take note.
The Motley Fool May 25, 2005 Tom Taulli	Genentech's Vision Thing Genentech has been on fire. Now the challenge will be to manage the growth. Investors, take note.
The Motley Fool July 12, 2005 Charly Travers	Genentech Shines On The world's largest biotech has been a four-bagger since 2003. Is it too late to get in the game?
BusinessWeek August 26, 2010 Tom Randall	Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer.
The Motley Fool January 29, 2008 Brian Lawler	Genentech Adds to Avastin's Arsenal Genentech's lead drug Avastin gains another use -- just not the one investors expected.
BusinessWeek June 16, 2011 Langreth & Cortez	When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates.
The Motley Fool December 1, 2005 Brian Gorman	Glaxo Follows the Biotechs The company's new focus on cancer drugs looks like a good move. Investors, take note.
Chemistry World January 8, 2009 Victoria Gill	Breast cancer drug target crystallised The crystal structure of human aromatase, an enzyme that is a key drug target for treating breast cancer, has been solved by US scientists.
The Motley Fool April 14, 2008 Brian Lawler	Not a Bad Quarter for Genentech Two of its top drugs see speedy growth, but investors don't seem ecstatic about Genentech's first-quarter financial results.
The Motley Fool November 25, 2008 Brian Orelli	Genentech Exhales The biotech had everything to lose and almost nothing to gain with its recent clinical trial.
The Motley Fool December 6, 2007 Brian Lawler	Genentech Voted Down An FDA panel recommends against expanded use of Genentech's lead drug.
The Motley Fool March 15, 2005 Charly Travers	The Best Company I've Never Owned The history of Genentech's Avastin, which just completed another phase 3 clinical trial showing that Avastin is effective in the treatment of non-small cell lung cancer. The author laments missing the opportunity to invest.
American Family Physician March 15, 2004	Breast Cancer Risk Related to Type of Hormone Therapy Although several studies have demonstrated an increased risk of breast cancer in postmenopausal women taking oral hormone therapy, the risk related to each of the various forms of therapy is less clear.
The Motley Fool April 26, 2004 Alyce Lomax	Genentech's Lucky Day Genentech and OSI Pharmaceuticals jump in today's trading session after favorable trial results for a cancer drug.
BusinessWeek June 13, 2005 Catherine Arnst	Biotech, Finally The past 30 years of biological discoveries, insights into the human genome, and exotic chemical manipulation have unleashed a wave of biological drugs, many of them reengineered human proteins.
Chemistry World July 28, 2009 Michael Gross	DNA to direct and switch off chemo Researchers in the US have developed a new approach to cancer chemotherapy using short DNA strands to help target delivery of the drug directly to cancer cells, and 'call it off' should problems arise.